The G2Solutions project, led by Prof. Dr. Ir. Floris Foijer from the UMCG – ERIBA Research Institute, has received funding from PharmaNL under the PharmaNL Shared Development Infrastructure program for their five-year project. G2Solutions focuses on developing infrastructure for new drug development. “This project demonstrates that we can make unique technologies, such as single-cell sequencing and stem cell and organoid production, available to the world, creating new opportunities for drug development,” says Peter Ketelaar, director of LIFE Cooperative. The project involves close collaboration between UMCG/ERIBA, UMCG/Genetics, LIFE Cooperative, GenomeScan, and Pivot Park Screening Centre.
G2Solutions utilizes groundbreaking technologies, including single-cell genomics. This technology, in which UMCG is a global leader, allows for the analysis of the genome of individual cells. This is crucial for chronic and complex diseases such as cancer, where the genome of cancer cells often shows significant variations. Instead of obtaining an average picture from millions of cells in a tissue, single-cell sequencing provides insights into the genetic abnormalities of individual cells. “The unique aspect of our approach is that we can read the DNA of individual cells, allowing us to examine much more closely what is happening within a tumor,” explains Foijer.
The techniques being developed in the project not only have scientific value but also significant commercial applications. Floris Foijer emphasizes that one of the main goals is to explore whether these technologies can be made widely accessible and affordable for diagnostics and therapies. Peter Ketelaar adds: “The biggest challenge for the business side is to find the right product-market combinations that can lead to sustainable success. We need to make technologies that are currently working in the lab affordable and applicable for a broader and international market.”
The project aims to make this infrastructure available to other pharmaceutical and academic partners, both nationally and internationally. Pivot Park Screening Centre, GenomeScan, and LIFE Cooperative are involved in further developing and marketing these technologies. Brigitte Drees from Pivot Park Screening Centre: “In this project, we are using our expertise to accelerate and optimize the development of new technologies. With our extensive experience in high-content screening and bioprofiling services, we contribute to identifying promising leads for drug development, which is crucial for the success of this innovative project.”
Kees van den Berg, CEO of GenomeScan explains: “At GenomeScan, we have extensive knowledge and experience in developing existing sequencing technologies from academia into a commercial facility for pharmaceutical and biotech companies. We will also apply this expertise to this innovative project.”
Ultimately, the goal is to establish a commercial company that will continuously offer the acquired knowledge and improved techniques. Foijer: “It’s an exciting journey to see whether we can bring academic technology to the market within five years. This project brings together science, technology, and entrepreneurship – a unique opportunity to achieve groundbreaking innovations.”
Floris Foijer and Peter Ketelaar also share some tips for future grant applicants at PharmaNL. Peter emphasizes that a successful grant application requires both strong technology and experienced entrepreneurs with market knowledge. “The core technology must be solid and fairly unique,” he says. “Additionally, you need to involve people who know how to bring new products and technologies to market. Understand the landscape of the subsidy world and the requirements, such as those of the funding provider.”
Floris adds that intrinsic motivation for collaboration and openness is crucial. “You need to have the desire to make your resources available, not just to secure funding for your own organization,” he explains. “Creating truly open infrastructure requires a willingness to share and collaborate.”
The development of this project has been made possible with the support of the Municipality of Groningen and the Municipality of Assen, the Province of Groningen, Drenthe, and Fryslân.
Source text: PharmaNL
Photo: Mathilde Broekhuis and Laura Kempe (two professionals at ERIBA) at the robot, photographer Floris Foijer.
MimeCure heeft een investering van 3 miljoen euro binnengehaald voor de ontwikkeling van een regeneratief geneesmiddel voor de behandeling van chronische longziekten, zoals longfibrose. Dankzij deze financiering kan MimeCure de afronding van de preklinische fase versnellen en beginnen met de voorbereidingen voor klinische proeven, die volgens planning eind 2027 van start zullen gaan. De investeringsronde wordt geleid door Addington Investment Group en ondersteund door mede-investeerder Apsara Investments.
Turning plans into results: that is the central focus of the fifth LIFE Science Conference, taking place on Tuesday, 22 September 2026 at Forum Groningen. The LIFE Cooperative will bring together professionals, entrepreneurs, researchers and policymakers from the life sciences and health sector around one key question: how do we translate vision into concrete impact? The keynote speaker will be Peter Wennink, former CEO of ASML and one of the most influential leaders in the Dutch technology sector. In 2025, he presented his advisory report ‘The Road to Future Prosperity’, in which he advocates targeted investments in innovation to strengthen the Netherlands’ long-term earning capacity.
In the North, and in Groningen in particular, there are dozens of companies working on innovations in the fields of life sciences and health. There are many hidden gems among them, says Ronald Hesse, director of the LIFE Cooperative partnership. “Millions of patients worldwide have already benefited from innovations developed here in Groningen,” he says.
